Popat Sanjay, Zhao Dongbing, Chen Zhengming, Pan Hongchao, Shao Yongfu, Chandler Ian, Houlston Richard S
Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK.
Anticancer Res. 2007 Jan-Feb;27(1B):627-33.
The relationship between chromosome 18q allelic imbalance (AI) and survival in colorectal cancer (CRC) is unclear, and study design may have contributed to inconsistent results previously reported.
Two hundred and eighty tumours from CRC patients participating in a molecular sub-study from a single multicentre trial of adjuvant intra-portal 5-fluorouracil were genotyped at 5 chromosome 18q microsatellite markers, blinded to clinical data and prospective to follow-up. The relationship between overall survival and AI was examined.
Two hundred and fifty-five tumours were informative for AI. The overall rate of AI was 49%. AI was not associated with age, tumour site or size. There was no difference in five-year survival rate between patients with (60.0% SE 5.2%) and without AI (61.4% SE 5.0%), even after correcting for covariates (HR=1.17, 95%CI:0.79-1.74, p=0.4).
Our data does not [corrected] support chromosome 18q AI as an important marker of survival in the adjuvant setting. It should not, therefore, be used outside clinical trials.
18号染色体等位基因失衡（AI）与结直肠癌（CRC）生存率之间的关系尚不清楚，研究设计可能是导致先前报道结果不一致的原因。
对参与一项辅助性门静脉内5-氟尿嘧啶单中心多中心试验分子亚研究的CRC患者的280个肿瘤，在5个18号染色体q微卫星标记处进行基因分型，对临床数据设盲并进行前瞻性随访。研究了总生存率与AI之间的关系。
255个肿瘤可提供有关AI的信息。AI的总体发生率为49%。AI与年龄、肿瘤部位或大小无关。有AI（60.0%，标准误5.2%）和无AI（61.4%，标准误5.0%）的患者五年生存率无差异，即使在校正协变量后也是如此（风险比=1.17，95%置信区间：0.79-1.74，p=0.4）。
我们的数据不支持18号染色体q AI作为辅助治疗中生存率的重要标志物。因此，它不应在临床试验之外使用。
